Table 4.
Measurement of paraoxonase enzymatic activity in healthy controls and subgroups of temporal lobe epilepsy patients
|
PON1 activities
|
HC
|
Pure TLE
|
F
|
df
|
P
value
|
Partial eta squared
|
| CMPAase (U/mL) | 42.8 (1.7) | 28.8 (1.9) | 30.61 | 1/62 | < 0.001 | 0.331 |
| Arylesterase (U/mL) | 215.4 (10.8) | 156.4 (12.2) | 13.47 | 1/62 | 0.001 | 0.178 |
| MTS | ||||||
| CMPAase (U/mL) | 41.7 (1.5) | 25.6 (1.2) | 81.44 | 1/100 | < 0.001 | 0.449 |
| Arylesterase (U/mL) | 209.8 (9.4) | 139.4 (7.5) | 36.98 | 1/100 | < 0.001 | 0.270 |
| Pure MTS | ||||||
| CMPAase (U/mL) | 42.2 (1.8) | 27.3 (2.6) | 22.61 | 1/52 | < 0.001 | 0.303 |
| Arylesterase (U/mL) | 213.0 (10.8) | 139.5 | 14.65 | 1/52 | < 0.001 | 0.220 |
Data are results of univariate general linear model analysis and are shown as model-generated marginal estimated mean (SE) values after covarying for age, sex and body mass index. Pure TLE: Temporal lobe epilepsy without any psychiatric comorbidity; MTS: Established mesial temporal lobe sclerosis (thus including psychiatric comorbidities); Pure MTS: Established mesial temporal lobe sclerosis without any psychiatric comorbidity; TLE: Temporal lobe epilepsy; HC: Healthy controls; MTS: Mesial temporal sclerosis.